Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.


Oral delivery of proteins has been hampered by an array of difficulties. However, promising novel oral delivery systems have been developed. 5-CNAC, formulated with the peptide salmon calcitonin, is in phase III clinical trials for the treatment of osteoporosis or osteoarthritis and could become the first marketed oral peptide. This article reviews key… (More)
DOI: 10.1177/0091270010372625